PGENPrecigen, IncSigning up patients
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Cervical Cancer · HPV-Related Carcinoma · HPV-Related Malignancy · Recurrent Cervical Carcinoma · Metastatic Cervical Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.5
5 insiders sold shares within a month
Since May 28, 2026 · was worth 10, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 24 (planned)
- Started
- Nov 11, 2025
- Main results expected
- Nov 11, 2026
- Fully finished
- Nov 30, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
Measured over: 1 year
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.5, since 2026-05-28, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06157151 · record last updated 2026-04-23 · checked 2026-11-09 15:47 UTC